98%
921
2 minutes
20
This article examines the effect that different specifications of the time trade-off (TTO) valuation task may have on values for EQ-5D-5L health states. The new variants of the TTO, namely lead-time TTO and lag-time TTO, along with the classic approach to TTO were compared using two durations for the health states (15 and 20 years). The study tested whether these methods yield comparable health-state values. TTO tasks were administered online. It was found that lag-time TTO produced lower values than lead-time TTO and that the difference was larger in the longer time frame. Classic TTO values most resembled those of the lag-time TTO in a 20-year time frame in terms of mean absolute difference. The relative importance of different domains of health was systematically affected by the duration of the health state. In the tasks with a 10-year health-state duration, anxiety/depression had the largest negative impact on health-state values; in the tasks with a 5-year duration, the pain/discomfort domain had the largest negative impact.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728436 | PMC |
http://dx.doi.org/10.1007/s10198-013-0507-y | DOI Listing |
Cureus
August 2025
Department of Internal Medicine, Babcock University Teaching Hospital, Ilishan-Remo, NGA.
Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a group of heterogeneous diseases with different pathological mechanisms. It is often under-recognized because of its diverse differential diagnoses like myocarditis, takotsubo cardiomyopathy, spontaneous coronary artery dissection (SCAD), coronary microvascular dysfunction, vasospasm, coronary erosion, and embolism. Evaluation with multimodality imaging including intravascular coronary imaging and cardiac magnetic resonance is often necessary to determine the underlying etiology and management.
View Article and Find Full Text PDFOrthop Surg
September 2025
Orthopedic Surgery Department, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Lateral patellar dislocation (LPD) is a musculoskeletal condition characterized by a complex etiology. Despite significant advancements in management strategies, it continues to pose considerable challenges. Critical anatomic risk factors previously identified include trochlear dysplasia (TD), patella alta, and elevated tibial tubercle-trochlear groove (TT-TG) distance, with TD being the most significant.
View Article and Find Full Text PDFJ Parasit Dis
September 2025
Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
is a protozoan parasite that infects more than a third of the world's population. The drugs used today to treat toxoplasmosis cause severe side effects in many people and have poor success in treating chronic infections. In the current study, oil extracted from tea leaf was loaded into solid lipid nanoparticles (SLNs) and its anti- properties were analyzed.
View Article and Find Full Text PDFCureus
July 2025
Paediatric Surgery, San Fernando Teaching Hospital, San Fernando, TTO.
Proximal ureteral atresia is an exceedingly rare presentation of congenital or neonatal hydronephrosis. We report the case of a full-term, female neonate born with an abdominal mass. On palpation, the mass occupied the right flank, and CT showed features suggestive of multicystic dysplastic kidney (MCDK).
View Article and Find Full Text PDFSci Rep
September 2025
Department of Orthopaedics, Tonglu branch Hospital, Hangzhou First People's Hospital, No.899 Meilin Road, Tonglu, Hangzhou, 330000, Zhejiang Province, China.
Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. This study aimed to characterize the real-world adverse event(AE) profile associated with triptorelin using data from the FDA Adverse Event Reporting System(FAERS). We conducted a retrospective pharmacovigilance study utilizing FAERS reports from the first quarter of 2004 to the third quarter of 2024 (2004Q1-2024Q3).
View Article and Find Full Text PDF